

Clinical Trial Protocol

Iranian Registry of Clinical Trials

04 Jul 2026

Trabeculectomy with versus without intravitreal bevacizumab in diabetic patients

Protocol summary

Summary

This is a prospective, randomized, comparative study at Rassoul Akram Hospital, Tehran, Iran to compare the outcome of trabeculectomy with versus without intravitreal injection of bevacizumab in diabetic patients. 52 eyes from 52 diabetic patients with uncontrolled glaucoma will be enrolled. The eyes will be assigned randomly to 2 groups: the bevacizumab group will undergo trabeculectomy with adjunctive intravitreal bevacizumab and the control group will undergo trabeculectomy without intravitreal bevacizumab. The outcome measures are best-corrected visual acuity (BCVA), intraocular pressure (IOP), number of IOP lowering medications, complications, bleb morphologic features (based on the Indiana Bleb Appearance Grading Scale).

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT2014102219206N3**

Registration date: **2014-11-08, 1393/08/17**

Registration timing: **registered_while_recruiting**

Last update:

Update count: **0**

Registration date

2014-11-08, 1393/08/17

Registrant information

Name

Naveed Nilforoushan

Name of organization / entity

Eye Research Center, Rasoul Akram Hospital, Iran
University of Medical Sciences

Country

Iran (Islamic Republic of)

Phone

+98 21 6650 9162

Email address

nilforoushan.n@iums.ac.ir

Recruitment status

Recruitment complete

Funding source

vice chancellor of research, Iran university of Medical Sciences

Expected recruitment start date

2014-10-01, 1393/07/09

Expected recruitment end date

2016-11-30, 1395/09/10

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Trabeculectomy with versus without intravitreal bevacizumab in diabetic patients

Public title

Trabeculectomy with versus without intravitreal bevacizumab in diabetic patients

Purpose

Treatment

Inclusion/Exclusion criteria

Inclusion criteria: diabetic patients who are candidate for trabeculectomy (inadequately controlled glaucoma with maximally tolerated medical therapy or intolerance to antiglaucoma medications). Exclusion criteria: being pregnant or currently breast feeding; past history of any ocular surgery other than cataract surgery in more than 6 months before trabeculectomy; ocular surface infection over the previous 2 weeks; systemic thromboembolic events; neovascular glaucoma; concurrent cataract surgery; age younger than 18 years old; diabetic

retinopathy which needs lasertherapy or intravitreal injection of anti- VEGF over the previous 6 months or within 6 months after trabeculectomy.

Age

From **18 years** old

Gender

Both

Phase

3

Groups that have been masked

No information

Sample size

Target sample size: **52**

Randomization (investigator's opinion)

Randomized

Randomization description

Blinding (investigator's opinion)

Single blinded

Blinding description

Placebo

Not used

Assignment

Parallel

Other design features

Secondary Ids

empty

Ethics committees

1

Ethics committee

Name of ethics committee

ethics committee of Iran University of Medical Sciences

Street address

Iran,Tehran,Iran University of Medical Sciences

City

Tehran

Postal code

Approval date

2014-10-01, 1393/07/09

Ethics committee reference number

105/3168/93/3

Health conditions studied

1

Description of health condition studied

Glaucoma

ICD-10 code

H40

ICD-10 code description

Glaucoma

Primary outcomes

1

Description

Intra Ocular Pressure

Timepoint

Days1, 7, 14, 30, 60, 90 and 180 after trabeculectomy

Method of measurement

IOP measurement by Goldmann tonometry

Secondary outcomes

1

Description

rate of qualified sugical success

Timepoint

Days 1, 7, 14, 30, 60, 90 and 180 after trabeculectomy

Method of measurement

qualified success is IOP of 21mmHg or less and at least 20% reduction in the preoperative IOP with antiglaucoma medications where the number ofthem is less than that used before surgery.

2

Description

BCVA

Timepoint

Days 1, 7, 14, 30, 60, 90 and 180 after trabeculectomy

Method of measurement

The BCVA is measured by Snellen chart.

3

Description

number of antiglaucoma medications

Timepoint

Days 1, 7, 14, 30, 60, 90 and 180 after trabeculectomy

Method of measurement

number of drugs to control the IOP

4

Description

rate of complete surgical success

Timepoint

Days 1, 7, 14, 30, 60, 90 and 180 after trabeculectomy

Method of measurement

Complete surgical success is defined by IOP of 21mmHg or less and at least20 % reduction in the preoperative pressure without any antiglaucoma medications

5

Description

bleb evaluation results

Timepoint

months 1 and 6

Method of measurement

Bleb photographs are obtained at months 1 and at the last follow-up.Bleb photographs at the last follow-up are graded by a masked glaucoma specialist(N.Ni.) who compares the study photographs with standard

photographs , according to the Indiana Bleb Appearance Grading Scale ,which is based on extension,height,vascularization, and leakage.

Intervention groups

1

Description

All surgeries are carried out by a single experienced surgeon(N.Ni.). For all eyes, after creating the scleral flap, MMC 0.02%(0.2mg/mL)is applied using multiple thin sponges under the scleral flap between the sclera and Tenon capsule for 2 minutes. At the end of surgery, the conjunctiva is closed with10-0 nylon sutures. In the bevacizumab group after suturing the conjunctiva , 2.5mg (0.1mL)bevacizumab (Avastin) is injected intravitreally.

Category

Treatment - Drugs

2

Description

In the same fashion, trabeculectomy is performed in the control group, but without intravitreal bevacizumab injection.

Category

N/A

Recruitment centers

1

Recruitment center

Name of recruitment center

Rassoul Akram Hospital

Full name of responsible person

Acieh Eshaghi

Street address

City

Tehran

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

vice chancellor of research,Iran University of Medical Sciences

Full name of responsible person

Mohammadi

Street address

Tehran,Iran University of Medical Sciences

City

Tehran

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

vice chancellor of research,Iran University of Medical Sciences

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Eye Research Center,Rassoul Akram Hospital

Full name of responsible person

Acieh Eshaghi

Position

ophthalmology resident

Other areas of specialty/work

Street address

Eye Research Center,Rassoul Akram Hospital

City

Tehran

Postal code

Phone

+98 21 6650 9162

Fax

Email

acieh_eshaghi@yahoo.com

Web page address

Person responsible for scientific inquiries

Contact

Name of organization / entity

Eye Research Center, Rassoul Akram Hospital,Iran University of Medical Sciences

Full name of responsible person

Naveed Nilforoushan

Position

glaucoma fellowship

Other areas of specialty/work

Street address

Eye Research Center, Rassoul Akram Hospital

City

Tehran

Postal code

Phone

+98 21 6650 9162

Fax

Email

naveednil@yahoo.com

Web page address

Person responsible for updating data

Contact

Name of organization / entity

Eye Research Center, Rassoul Akram Hospital, Iran
University of Medical Sciences

Full name of responsible person

Naveed Nilforoushan

Position

glaucoma fellowship

Other areas of specialty/work**Street address****City****Postal code****Phone**

+98 21 6650 9162

Fax**Email**

naveednil@yahoo.com

Web page address

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty